About two-thirds of BMs from breast cancer are associated with the triple-negative breast cancer subtype (i.e., negative for estrogen and progesterone receptors, and no HER2 amplification) and the HER2-positive subtype [12]. Here, ERBB2 is linked to breast carcinoma.